Linquan Tang
State Key Laboratory Of Oncology In South China, Guangdong Key Laboratory Of Nasopharyngeal Carcinoma Diagnosis And Therapy
Guangzhou, China
Guangzhou, China
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 24 publications
Becotatug Vedotin Combined With Pucotenlimab in Platinum- and Immunotherapy-Resistant Recurrent or Metastatic Nasopharyngeal Carcinoma.
Journal: Journal of clinical oncology : official journal of the American Society of Clinical Oncology
Published: August 25, 2026
Izalontamab brengitecan, an EGFR and HER3 bispecific antibody-drug conjugate, versus chemotherapy in heavily pretreated recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 study in China.
Journal: Lancet (London, England)
Published: September 08, 2025
Correction: Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.
Journal: British journal of cancer
Published: August 27, 2025
The Tumor-to-Endothelial Transfer of FTO Promotes Vascular Remodeling and Metastasis in Nasopharyngeal Carcinoma.
Journal: Advanced science (Weinheim, Baden-Wurttemberg, Germany)
Published: May 26, 2025
Reproduction outcomes and prognostic significance of pregnancy after nasopharyngeal carcinoma treatment.
Journal: Annals of medicine
Published: February 03, 2025
Biomarkers of response to camrelizumab combined with apatinib: an analysis from a phase II trial in recurrent/metastatic nasopharyngeal carcinoma.
Journal: British journal of cancer
Published: November 10, 2024
Determining the optimal duration of oral adjuvant chemotherapy in locoregionally advanced nasopharyngeal carcinoma.
Journal: British journal of cancer
Published: October 01, 2024
Locoregional Radiotherapy Candidates in de Novo Metastatic Nasopharyngeal Carcinoma: Real-World Insights in the Immunotherapy Era.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 19, 2024
Anlotinib as a third-line or further treatment for recurrent or metastatic nasopharyngeal carcinoma: a single-arm, phase 2 clinical trial.
Journal: BMC medicine
Published: June 01, 2023
Radiomics and Deep Learning in Nasopharyngeal Carcinoma: A Review.
Journal: IEEE reviews in biomedical engineering
Published: April 25, 2023
Modulation Effects of the CEP128 Gene on Radiotherapy-Related Brain Injury: A Longitudinal Structural Study Using Multi-Parametric Brain MR Images.
Journal: Journal of magnetic resonance imaging : JMRI
Published: February 24, 2023
Last Updated: 09/26/2026